MedTrace Logo

Prenatal Antibiotics and Breast Milk / Neonatal IgA

NCT05813184 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2024-06-26

No results posted yet for this study

Summary

In this biological study, the investigators will evaluate the levels of breast milk IgA, neonatal fecal IgA, and the composition of breast milk and fecal microbiota throughout the first 12 months of life in neonates born to mothers treated or not treated with prenatal antibiotics for at least 7 days after the 32nd weeks of gestation

Conditions

  • Prenatal Exposure Delayed Effects
  • Antibiotic Prophylaxis
  • Dysbiosis
  • Neonatal Infection
  • Breast Milk; Noxious Influence, Affecting Fetus

Interventions

DRUG

Antibiotics

Any antibiotic therapy administered \> 7 days

Sponsors & Collaborators

  • Humanitas Hospital, Italy

    collaborator OTHER

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    lead OTHER

Principal Investigators

  • Carlo Pietrasanta, MD,PhD · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-08
Primary Completion
2025-04-30
Completion
2025-10-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813184 on ClinicalTrials.gov